Pharmaceut Reg Affairs 2012, 1:4
http://dx.doi.org/10.4172/2167-7689.S1.008

OMICS Group Conferences
Accelerating Scientific Discovery

2nd International Conference and Exhibition on
Pharmaceutical Regulatory Affairs

November 23-24, 2012 Hyderabad International Convention Centre, India

Ethical issues in vaccine clinical trials

B.D. Darade and A.S. Khairnar
Maharashtra University of Health Sciences, India

Participation of children in vaccine trials is a complex, legal, and ethical issue. Greater efforts should be made to develop vaccines in developing countries. Such trials involve not only significant scientific challenges but also complex economic & ethical considerations, Paediatric age groups are significantly vulnerable as a research subject, in a vaccine trials conducted in developing countries. Such trial should be justified with the participated populations. There should be equitable sharing of benefits and risks. Ethically and scientifically explanation about the use of population. End point priority after vaccine trial is to improve child survival and prevention of diseases & to overcome the morbidity and mortality. The inform consent form should explain the purpose, risk & benefits, comparator & care. It should be voluntarily and inform. This topic explains vulnerability of child, benefits and risk, adolescent participation, inform consent/confidentiality, compensation, and regulatory framework.

Biography

I did my medical graduation in B.H.M.S. Myself is doing PG.in Pharmaceutical Medicine From "University Department of Interpathy Research and Technology (UDIRT)",Maharashtra University of Health Sciences (MUHS), Nashik.

bddarade@gmail.com

New therapeutics for inflammation and leukemia: Targeting PI3k isoforms and ship

B. Raja Shekhar
Anurag Group of Institutions, India

PI3K is critical for the normal function of the immune system, however dysregulated PI3K mediated signaling has been linked to the development of many immune mediated pathologies. This review describes current progress in the development of isoform-specific PI3K inhibitors that hold promise for the treatment of hematopoietic malignancies as well as for inflammatory and autoimmune diseases. A SH2-domain containing inositol-5-phosphatase (SHIP) is a regulator of PI3K signaling, and is also discussed as a potential drug target for immunomodulation and the treatment of leukemia. Recent progress has been made in the development of small molecule compounds that potently and selectively modulate SHIP activity and hence provide a novel mechanism to alter PI3K mediated signaling.

raj.shivam999@gmail.com